Evidence Database
See what is known—and what is still missing.
Explore the sources, assumptions and evidence gaps behind regulatory information, impact estimates and transition-finance scenarios.
Verified
Checked against its source and reviewed for scope, dates and units.
Reported
A published estimate or statement attributed to its source.
Modelled
A transparent platform scenario, formula or editable assumption.
Data Gap
Information remains unknown; no numeric result is implied.
19 evidence records
Ten countries in the 30-country European study area had notified national rules permitting some form of regulated single-use medical-device reprocessing through January 2025.
Comparable device-level procurement prices and full programme costs are not reported across the study area.
IHLEG estimates approximately US$2.4 trillion per year by 2030 for emerging and developing economies excluding China.
IHLEG estimates that global climate investment needs to rise to approximately US$6.5 trillion per year by 2030.
IHLEG identifies a dedicated just-transition component of approximately US$40 billion per year by 2030.
McKinsey estimates average annual spending on physical assets for the net-zero transition at US$9.2 trillion from 2021 to 2050.
Verified bills of materials are not available for the device scenarios represented on this platform.
Verified device-to-country and mine-level sourcing links are not available.
Comparable annual successful clinical-use volumes across the European study area are not reported.
A reviewed aggregate annual net-savings figure for the current 10-country baseline is not available.
The Transition Finance illustrative scenario starts with a 1.0× activity factor for countries beyond the 10-country baseline.
The Transition Finance illustrative scenario starts with a voluntary allocation of 1% of positive net benefit.
The calculator starts at €0 additional programme cost only because costs have not been entered.
The Transition Finance illustrative scenario starts with a 35% discount versus the new-device price.
The Transition Finance illustrative scenario starts with a €450 new-device price.
The Transition Finance illustrative scenario starts with 1,000,000 eligible successful device uses per authorising country per year.
ActionAid reports that 2.8%, or approximately US$630 million, of the GCF/CIF mitigation finance examined over more than a decade supported just-transition criteria.
Measured worker and community outcomes attributable to SUMD reprocessing or related allocations are not reported.
Verified transfers of European hospital reprocessing savings to Global South just-transition priorities are not reported.
Evidence-gap register
Comparable device-level procurement prices and full programme costs are not reported across the study area.
GAP-BOMVerified bills of materials are not available for the device scenarios represented on this platform.
GAP-MINE-TRACEVerified device-to-country and mine-level sourcing links are not available.
GAP-UPTAKE-VOLUMEComparable annual successful clinical-use volumes across the European study area are not reported.
GAP-AGG-SAVINGSA reviewed aggregate annual net-savings figure for the current 10-country baseline is not available.
GAP-OUTCOMESMeasured worker and community outcomes attributable to SUMD reprocessing or related allocations are not reported.
GAP-TRANSFERSVerified transfers of European hospital reprocessing savings to Global South just-transition priorities are not reported.
Public update history
The first public release established linked sources, modelled Transition Finance assumptions, eligible annual benchmarks and an explicit evidence-gap register. Future approved changes will be recorded on each evidence record.
Regulatory scanner connection: Not connected. Detected changes cannot alter published records automatically.